个股
共 6,276 份研报 · 国内 4,017 · 国外 1,840
艾伯维(ABBV.N):ABBV-466提升实现更深层克罗恩病缓解及延长Skyrizi生命周期的潜力
AbbVie (ABBV.N): ABBV-466 raises the potential for deeper Crohn's responses and Skyrizi lifecycle extension
花旗·2026-10-19·11 页·美股
Silgan Holdings(SLGN.N):对收购Trivium的初步看法——估值具吸引力,或释放资产组合价值
Silgan Holdings Inc (SLGN.N): First Thoughts on Trivium Acquisition - Attractive Multiple, May Unlock Portfolio Value
花旗·2026-10-19·10 页·美股
ORIC Pharmaceuticals(ORIC.O):Enozertinib达80%的一线客观缓解率与中枢神经系统活性继续支持其潜在差异化优势
Enozertinib's 80% 1L cORR and CNS Activity Continue to Support Potential Differentiation
花旗·2026-10-19·11 页·美股
Monolithic Power Systems(MPWR.O)2026年第三季度业绩前瞻:企业数据与通信业务势头加速
Monolithic Power Systems (MPWR.O) 3Q26 Earnings Preview: Enterprise Data and Communications Momentum Accelerating
花旗·2026-10-19·16 页·美股
MiniMax(0100.HK)M3.1 Flash发布:重塑企业级智能体经济学
MiniMax (0100.HK) M3.1 Flash Release: Reshaping Enterprise Agent Economics
花旗·2026-10-19·11 页·港股
27.1个月HLA阳性mOS强化Daro广谱标签论据;IDE849的12个月OS显示相较Imdelltra的差异化优势
27.1-Month HLA-Pos. mOS Bolsters Daro’s Broad Label Case; IDE849’s 12-Month OS Suggests Differentiation vs. Imdelltra
花旗·2026-10-19·11 页·美股
EyePoint(EYPT.A):湿性黄斑变性研发路径因第二次三期临床失败而关闭,目标价下调至4美元(下调13美元),公司重新聚焦糖尿病性黄斑水肿(DME)故事
EyePoint Inc (EYPT.A): wAMD Pathway Shutters with Second Ph3 Miss. Lowering TP to $4 (-$13). EYPT Refocuses Into a DME Story
花旗·2026-10-19·13 页·美股
AppLovin广告周第42期:美国应用商店增长加速
AppLovin Ads Week #42: US Store Growth Accelerating
花旗·2026-10-19·15 页·美股
中国软件国际(0354.HK):中国AI驱动未来增长;评级卖出
Chinasoft Intl (0354.HK): China AI to drive growth ahead; Sell
高盛·2026-10-19·9 页·港股
长鑫存储(688825.SS):AI驱动DRAM需求,环比增长在即;26年第三季度营收环比增长15%~20%;维持买入
CXMT (688825.SS): Sequential QoQ growth ahead on AI driving DRAM demand; 3Q26 revenues +15%~20% QoQ; Buy
高盛·2026-10-19·7 页·科创板
深度连线:探讨将CoreWeave(CRWV)评级上调至买入
Research Unplugged: Discussion of our upgrade of CoreWeave (CRWV) to Buy
高盛·2026-10-19·8 页·美股
克利夫兰克里夫(CLF):2026年第三季度业绩初评;业绩超预期且势头持续向好
Cleveland-Cliffs Inc. (CLF): 3Q26 Earnings First Take; Earnings Beat and Momentum Continues to Improve
高盛·2026-10-19·7 页·美股
杰富瑞金融集团(JEF)2026年投资者日:核心纪要
Jefferies Financial Group (JEF) 2026 Investor Day: Key takeaways
北京高华证券·2026-10-19·10 页·美股
吉利德科学(GILD):口服α₄β₇治疗溃疡性结肠炎的二期数据令人鼓舞
Gilead Sciences Inc. (GILD): Encouraging Phase 2 data for oral α₄β₇ in ulcerative colitis
高盛·2026-10-19·8 页·美股
艾伯维(ABBV):二期炎症性肠病数据更新证实新一代项目的惊艳疗效
AbbVie Inc. (ABBV): Ph2 IBD Data Update Confirms Impressive Efficacy of Next-Gen Program
高盛·2026-10-19·7 页·美股
Tradeweb Markets(TW):宣布以约20亿美元收购Trumid
Tradeweb Markets Inc. (TW): Announced acquisition of Trumid for ~$2bn
高盛·2026-10-19·7 页·美股
Silence Therapeutics Plc(SLN):默克集团将以13亿美元交易价值收购SLN,预计2027年一季度完成交割
Silence Therapeutics Plc (SLN): Merck KGA to Acquire SLN for Deal Value of $1.3B, Deal Expected to Close in 1Q27
高盛·2026-10-19·6 页·美股
CoreWeave(CRWV):上调评级至买入——合同经济学的未来十二个月数据点可能比市场预期更积极
CoreWeave Inc. (CRWV): Upgrade to Buy: NTM datapoints on contract economics are likely to be more positive than the market expects
高盛·2026-10-19·19 页·美股
微软2027财年第一季度前瞻:Azure与Office能否双双加速?
Microsoft 1Q27 preview: Could Azure and Office both accelerate?
伯恩斯坦·2026-10-19·22 页·美股
Fervo Energy Company(FRVO.US):验证的代价
伯恩斯坦·2026-10-19·20 页·美股
显示 3861 - 3880 条,共 6,276 条